Hy-Vee health

ILUMYA
Infusion Orders

PHONE 515.225.2930 | **FAX** 515.559.2495

Patient Information

Fax completed form, insurance information and clinical documentation to 515.559.2495.

Patient Name: _____ **DOB:** _____ **Phone:** _____

Patient Status: ☐ New to Therapy ☐ Continuing Therapy **Next Treatment Date:** _____

Medical Information

Diagnosis: ☐ Plaque psoriasis (ICD-10 code: L40.0)

☐ Other: _____ **ICD-10 Code:** _____

Patient Weight: _____ lbs. (required) **Allergies:** _____

Therapy Order

Initial dosing (New Start):

☐ 100 mg subcutaneously at weeks 0 and 4, then every 12 weeks thereafter x1 year

OR

Maintenance dosing:

☐ 100 mg subcutaneously every 12 weeks x1 year

Lab Orders: _____ **Lab Frequency:** _____

☐ Yearly TB QFT screening (optional)

Required labs to be drawn by: ☐ Infusion Center ☐ Referring Provider

Provider Information

By signing this form and utilizing our services, you are authorizing *Hy-Vee Health* and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

Provider Name: _____ **Signature:** _____ **Date:** _____

Provider NPI: _____ **Phone:** _____ **Fax:** _____ **Contact Person:** _____

☐ Opt out of Hy-Vee Health selecting site of care (if checked, please list site of care): _____

Service Areas

☐ Des Moines, IA ☐ West Des Moines, IA ☐ Chicago, IL ☐ Omaha, NE ☐ Buffalo, NY ☐ Dallas, TX

☐ Phoenix, AZ ☐ Other _____

HY-VEEHEALTHINFUSION.COM

COMPREHENSIVE SUPPORT FOR ILUMYA THERAPY

Patient Information

Patient Name: _____ **DOB:** _____

Required Documentation for Referral Processing & Insurance Approval

☐ Include signed and completed order (MD/prescriber to complete page 1)

☐ Include patient demographic information and insurance information

☐ Include patient's medication list

☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits or contraindications to conventional therapy

- ☐ Has the patient had a documented contraindication/intolerance or failed trial of a corticosteroids, vitamin D analogs, calcineurin inhibitors or Anthralin? ☐ Yes ☐ No

  If yes, which drug(s)? _____

- ☐ Percent of body surface (BSA) involved: _____ %

- ☐ Has the patient tried and failed methotrexate? ☐ Yes ☐ No

- ☐ Does the patient have a contraindication/intolerance or failed trial to any biologics (i.e., Humira, Skyrizi, Tremfya, Cosentyx, Stelara, Cimzia)? ☐ Yes ☐ No

  If yes, which drug(s)? _____

☐ Include labs and/or test results to support diagnosis

☐ Is the patient or caregiver not competent or physically unable to administer Ilumya for self-administration? ☐ Yes ☐ No

☐ Other Medical Necessity: _____

Required Prescreening

☐ **TB screening test completed within 12 months – attach results**

- ☐ **Positive** ☐ **Negative**

*If TB or Hepatitis B results are positive, please provide documentation of treatment or medical clearance, and a negative CXR (TB+)

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.